Current Affairs
Cough Syrup Deaths in India: Understanding the Contamination Crisis and Regulatory Response
The deaths of at least 16 children in Madhya Pradesh from contaminated cough syrup (Coldrif) warrants the need to understand the causes plaguing the drug regulatory system.
The recent deaths of children due to consumption of cough syrup have exposed gaps in pharmaceutical safety oversight. At least 16 children, mostly under five years of age, died after consuming contaminated Coldrif cough syrup manufactured by Sresan Pharmaceuticals in Tamil Nadu.
Laboratory testing revealed the contaminated batch contained 48.6% diethylene glycol (DEG), 480 times the permissible limit of 0.1%. This crisis highlights the need for drug quality control and regulatory reform in India’s pharmaceutical sector.
Understanding the Toxic Contaminants: DEG and EG
Diethylene glycol (DEG) and ethylene glycol (EG) are colorless industrial chemicals used in manufacturing brake fluids, antifreeze, paints, plastics, and certain household items. However, they have no role in medicines intended for human use.
Propylene glycol is a safer pharmaceutical-grade solvent usually used to dissolve active ingredients in cough syrups. However, as DEG and EG are cheaper, some manufacturers illegally use them as a substitute for propylene glycol to reduce production costs.
When ingested, DEG is metabolized in the liver into toxic compounds such as oxalic acid, which forms sharp crystals that deposit in kidney tubules, causing rapid kidney failure.
India’s History with Toxic Syrups
The Coldrif tragedy is not an isolated incident. India has witnessed several cough syrup deaths over the past three decades:
- In 1998, 33 children died in Gurugram after consuming syrup containing DEG, with 150 children hospitalized with acute kidney failure in Delhi.
- In 2020, 17 children died in Jammu and Kashmir’s Ramnagar after taking contaminated cough syrup with DEG.
- In 2022, India’s reputation as the ‘Pharmacy of the World’ suffered when cough syrups manufactured in India were linked to 70 child deaths in The Gambia and 18 deaths in Uzbekistan.
Understanding the Regulatory System
India’s drug regulation functions under the Drugs and Cosmetics Act, 1940 and Rules, 1945, through a dual control structure. The Central Drugs Standard Control Organisation (CDSCO), led by the Drugs Controller General of India (DCGI), manages central licensing, new drug approvals, and policy formulation. State Drug Controllers oversee manufacturing and sales licenses, inspections, and enforcement.
Key legal provisions, define drug quality standards, prohibit misbranding and adulteration, and impose strict penalties for violations.
Schedule M of the Rules outlines Good Manufacturing Practices (GMP), prescribing norms for premises, equipment, hygiene, documentation, and quality assurance. Compliance with Schedule M is mandatory to ensure that all drugs manufactured in India meet required standards of safety, efficacy, and quality.
Issues with the System
Regulatory Challenges
India’s fragmented dual control system creates significant vulnerabilities in drug safety oversight. While the Central Drugs Standard Control Organisation (CDSCO) sets national policy, individual State Drug Controllers handle enforcement. This results in inconsistent safety standards and implementation across the country. This means drug quality standards vary by state, leaving the national safety net only as strong as its weakest regulator.
The infrastructure gaps are also concerning. A 2023 parliamentary review revealed that nearly half of India’s state drug testing laboratories lack proper equipment or qualified analysts for effective surveillance. Moreover, budget constraints force many smaller facilities to rely on outdated methods and techniques for testing.
Manufacturing Issues
The detection of 48.6% DEG content in Coldrif suggests deliberate substitution rather than accidental contamination. This practice is enabled by several systemic weaknesses: weak accountability enforcement that prioritizes license cancellations over criminal prosecution of responsible personnel.
Contamination can occur through multiple pathways:
- Inadequate quality control at manufacturing facilities that fail to test incoming raw materials
- Compromised supply chains where suppliers provide substandard or deliberately mislabeled ingredients
- Cross-contamination in mixing equipment that isn’t properly cleaned between production batches
- Deliberate substitution of pharmaceutical-grade solvents with industrial alternatives to maximize profit margins
Implementation Barriers
Regulatory compliance requires significant investment in infrastructure, testing equipment, and training. Small and medium enterprises lack capital for these upgrades. Without financial support mechanisms like subsidies or low-interest loans, compliance costs could force smaller firms out of business while failing to address contamination’s root causes.
Government Response
In response to the Coldrif crisis, the Union Health Ministry has ordered strict compliance with revised Schedule M norms, updated GMP standards under the Drugs and Cosmetics Act, 1940. The Rajasthan government also banned cough syrups containing Dextromethorphan for children under five years of age.
The new norms, effective by December 31, 2025, mandate Quality Risk Management, supply chain traceability, DEG/EG testing, data integrity, and pharmacovigilance systems. Additionally, Madhya Pradesh banned Coldrif syrup sales statewide and requested Tamil Nadu to investigate the Kanchipuram manufacturing facility.
The Union Health Ministry issued advisories to all States/UTs against prescribing cough-cold medications to children below two years. In addition, these are generally not recommended for children below five years.
Above that, any use should follow careful clinical evaluation with close supervision and strict adherence to appropriate dosing and avoiding multiple drug combinations. Non-compliant manufacturing units risk license cancellation, marking a major push for safety and accountability in India’s pharmaceutical sector.
Path Forward
The Coldrif cough syrup deaths serve as a reminder that pharmaceutical safety cannot be compromised. Several reforms are needed:
- Unified regulatory authority: Centralizing key enforcement powers under CDSCO or a new Unified Drug Safety Authority would eliminate state-to-state variations.
- Equal standards for all markets: Mandatory testing requirements for exports must be extended to all domestically distributed medicines.
- Laboratory upgrades: State drug testing facilities must be equipped with advanced analytical instruments and trained personnel.
- Financial support for compliance: Small-Medium Enterprises (SMEs) need assistance to meet new infrastructure and system requirements.
- Real-time pharmacovigilance: A centralized adverse event reporting system linking hospitals to CDSCO could enable identification of contaminated batches.
- Accountability: Criminal prosecution must target company promoters and responsible personnel, not just revoke licenses.
Conclusion
The contamination crisis has exposed weaknesses in India’s pharmaceutical safety framework. While the government’s push for Schedule M compliance is a step forward, implementation requires addressing the fragmented regulatory structure, investing in testing infrastructure, and ensuring equal protection for domestic consumers.
Only through reform, accountability, and commitment to quality can we prevent future tragedies and restore trust in India’s pharmaceutical sector. Medicine meant to heal should never harm, this principle must guide every aspect of drug manufacturing and regulation.
Master Digital Age Governance & Technology Trends with VisionIAS Comprehensive Current Affairs →
FAQs: Cough Syrup Contamination Crisis in India
1. What toxic chemical was found in Coldrif cough syrup?
Ans. Diethylene glycol (DEG) at 48.6%.
2. What is the permissible limit of diethylene glycol in medicines?
Ans. 0.1 percent maximum.
3. What are the symptoms of diethylene glycol poisoning?
Ans. Kidney failure caused by toxic oxalic acid crystals.
4. What is Schedule M in Indian pharmaceutical regulations?
Ans. Good Manufacturing Practices regulations under the Drugs and Cosmetics Act, 1940.
5. Why do manufacturers use diethylene glycol in cough syrups?
Ans. To cut costs by replacing pharmaceutical-grade propylene glycol with cheaper industrial chemicals.
